Moderna (MRNA) Peer Comparison
$140.34
$2.35
(1.70%)
As on 31-Aug-2026 16:28EDT
Market cap
$55,091 Mln
Revenue (TTM)
$2,228 Mln
P/E Ratio
--
P/B Ratio
8.4
Div. Yield
0 %
Edit
| Moderna (MRNA) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Revolution Medicines (RVMD) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
55,091 | 137,210 | 81,766 | 44,556 | 42,612 |
Revenue ($ Mln) |
2,228 | 12,624 | 15,535 | -- | 16,983 |
Net Profit ($ Mln) |
-3,151.00 | 4,405.20 | 4,328.70 | -1,768.29 | 1,375.00 |
Net Margin (%) |
-141.43 | 34.89 | 27.86 | -- | 8.10 |
RoE (%) |
-40.89 | 22.64 | 13.75 | -83.46 | 21.63 |
Price to Earnings |
-- | 31.51 | 19.66 | -- | 32.20 |
Price-To-Book |
8.43 | 6.85 | 2.62 | 18.19 | 6.65 |
Income Statement ($ Mln)
| Moderna (MRNA) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Revolution Medicines (RVMD) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2,228.00 | 12,624.30 | 15,534.70 | 0.00 | 16,983.00 |
|
Cost of Revenue
|
2,508.00 | 1,762.80 | 2,352.10 | 9.24 | 12,528.00 |
|
Gross Profit
|
1,076.00 | 10,267.50 | 12,242.20 | -16.56 | 4,286.00 |
|
Operating Expenses
|
3,040.00 | 5,989.90 | 9,212.50 | 1,618.01 | 2,150.00 |
|
Operating Profit (EBIT)
|
-3,320.00 | 4,872.00 | 3,970.10 | -1,627.25 | 2,305.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-3,087.00 | 5,274.90 | 5,166.00 | -1,768.29 | 1,609.00 |
|
Provision for Tax
|
64.00 | 869.30 | 837.30 | 0.00 | 253.00 |
|
Profit after Tax (Net Income)
|
-3,151.00 | 4,405.20 | 4,328.70 | -1,768.29 | 1,375.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | -4.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 845.00 |
Liabilities ($ Mln)
| Moderna (MRNA) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Revolution Medicines (RVMD) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
6,761.00 | 20,247.90 | 31,711.00 | 2,606.24 | 6,171.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | -4.00 |
|
Non-Current Liabilities
|
1,666.00 | 3,237.50 | 4,488.60 | 1,362.97 | 14,765.00 |
|
Current Liabilities
|
2,534.00 | 3,937.90 | 5,530.60 | 354.06 | 8,815.00 |
|
Total Liabilities
|
12,338.00 | 26,142.80 | 40,558.70 | 2,354.51 | 29,944.00 |
Assets ($ Mln)
| Moderna (MRNA) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Revolution Medicines (RVMD) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
5,146.00 | 14,879.60 | 23,284.00 | 294.93 | 23,655.00 |
|
Current Assets
|
5,815.00 | 12,543.70 | 18,446.00 | 4,028.34 | 6,226.00 |
|
Total Assets
|
12,338.00 | 26,142.80 | 40,558.70 | 2,354.51 | 29,944.00 |
|
Total Debt*
|
1,287.00 | 1,977.60 | 1,986.60 | 641.93 | 16,241.00 |
|
Net Current Assets
|
3,281.00 | 8,605.80 | 12,915.40 | 3,674.28 | -2,589.00 |
Cashflow ($ Mln)
| Moderna (MRNA) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Revolution Medicines (RVMD) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-1,873.00 | 3,631.40 | 4,978.90 | -897.74 | 2,654.00 |
|
Cash Flow from Investing Activities
|
1,946.00 | -945.40 | -629.10 | 118.06 | -2,305.00 |
|
Cash from Financing Activities
|
593.00 | -2,261.30 | -3,715.40 | 621.52 | -150.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Moderna (MRNA) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Revolution Medicines (RVMD) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-25.41 | 19.42 | 13.65 | -53.99 | 6.34 |
|
ROE (%)
|
-40.89 | 22.64 | 13.75 | -83.46 | 21.63 |
|
ROA (%)
|
-23.27 | 14.80 | 9.71 | -48.50 | 3.67 |
|
EBIT Margin (%)
|
-137.79 | 41.83 | 33.61 | -- | 13.81 |
|
Net Margin (%)
|
-141.43 | 34.89 | 27.86 | -- | 8.10 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | -- | 0.00 |
Growth Ratios
| Moderna (MRNA) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Revolution Medicines (RVMD) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-27.19 | 10.56 | 9.29 | -- | 8.17 |
|
EBIT Growth (%)
|
-4.74 | 20.31 | 6.31 | -33.90 | 5.30 |
|
Net Profit Growth (%)
|
-8.54 | 21.10 | -2.91 | -117.75 | 11.16 |
|
EPS Growth (%)
|
-6.34 | 22.80 | 1.72 | -95.21 | 16.60 |
|
Book Value Growth (%)
|
-29.52 | 19.36 | 7.70 | 24.65 | 9.72 |
Valuation Ratios
| Moderna (MRNA) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Revolution Medicines (RVMD) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-4.10 | 29.37 | 18.42 | -13.39 | 28.49 |
|
Price / Book Value
|
1.34 | 6.22 | 2.65 | 9.28 | 5.96 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-3.01 | 23.31 | 13.25 | -12.17 | 15.24 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Moderna (MRNA) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Revolution Medicines (RVMD) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.09 | 0.00 | 0.06 | 0.19 | 2.22 |
|
Short term debt to equity ratio
|
0.01 | 0.00 | 0.00 | 0.01 | 0.37 |
|
Current Ratio
|
2.29 | 3.19 | 3.34 | 11.38 | 0.71 |
|
Quick Ratio
|
2.18 | 2.74 | 2.78 | 11.38 | 0.71 |
|
Interest Coverage
|
-72.50 | 800.23 | 94.25 | -28.80 | 3.09 |
Operating Efficiency Ratios
| Moderna (MRNA) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Revolution Medicines (RVMD) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
4.62 | 16.91 | 42.26 | -- | 19.94 |
|
Asset Turnover
|
0.16 | 0.42 | 0.35 | 0.00 | 0.45 |
|
Receivable days
|
82.29 | 55.39 | 152.19 | -- | 74.65 |
|
Inventory Days
|
56.81 | 292.28 | 546.66 | -- | -- |
|
Payable days
|
151.91 | 88.40 | 150.27 | 1,312.97 | 68.15 |
|
Cash Conversion Cycle
|
-12.81 | 259.28 | 548.59 | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
